GlassScriptPhysician profile
Rebecca A Levine
NPI 1457506107
$3,653.39
in general payments reported to CMS, 2019-2025
14 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $596 · 2021: $217 · 2022: $1,446 · 2023: $234 · 2024: $237 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,882.97 | 2021-2024 | Bulkamid, Axonics |
| Medtronic USA, INC. | $925.01 | 2019-2020 | |
| Covidien LP | $325.00 | 2019 | |
| Boston Scientific Corporation | $119.22 | 2025 | Bulkamid |
| Ethicon US, LLC | $109.54 | 2024 | Echelon Circular, Echelon Flex, Stratafix |
| Kerecis Limited | $79.96 | 2022-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Tela Bio, INC. | $57.43 | 2019 | |
| Medtronic, INC. | $42.30 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.97 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.87 | 2025 | Gattex |
| Abbvie INC. | $20.08 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $17.57 | 2025 | |
| Innovation Technologies INC | $16.89 | 2020 | |
| Thd America, INC. | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.